Markets ZYME

Zymeworks Issues Updated 2026 Financial Guidance

September 28, 2026 — 06:36 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Zymeworks (ZYME) said the company now expects total revenue for 2026 to be between $278 million and $292 million and 2026 adjusted EBITDA to be between $114 million and $128 million, excluding the impact of any future transactions. The company announced the updated financial guidance following the completion of its acquisition of Theravance Biopharma.

The acquisition added YUPELRI to Zymeworks' portfolio. Through Theravance Biopharma's collaboration with Viatris, Zymeworks is entitled to a 35% share of net U.S. profits from YUPELRI and royalties on net sales outside the United States. In the first half period, YUPELRI sales of $133.1 million resulted in collaboration revenue to Theravance of $38.4 million.

In pre-market trading on NasdaqGS, Zymeworks shares are down 0.87 percent to $26.29.

For More Such Health News, visit rttnews.com.

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

Markets
Stocks Mentioned
ZYME

Latest Articles
Data is currently not available